Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: Is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?

General and Comparative Endocrinology

Volumn 188, Issue 1, 2013, Pages 282-287

  Kohler, S ^a   Tschopp, O ^a   Sze, L ^a,b   Neidert, M ^a   Bernays, R L ^a   Spanaus, K S ^c   Wiesli, P ^d   Schmid, C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Department of Endocrinology and Diabetes ^*  (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Kantonsspital Frauenfeld   (Switzerland)

Author keywords

Acromegaly; Alpha Klotho; Diagnosis; Growth hormone receptor; Insulin like growth factor 1; Monitoring

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; KLOTHO PROTEIN; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; CLINICAL ARTICLE; DISEASE ACTIVITY; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; MALE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 84878931611     PISSN: 00166480     EISSN: 10956840     Source Type: Journal    
DOI: 10.1016/j.ygcen.2013.04.024     Document Type: Article

References (45)

1. Akimoto T., Yoshizawa H., Watanabe Y., et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012, 13:155.
2. Akimoto T., Kimura T., Watanabe Y., et al. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant. Proc. 2013, 45(1):134-136.
3. Alexander R.T., Woudenberg-Vrenken T.E., Buurman J., et al. Klotho prevents renal calcium loss. J. Am. Soc. Nephrol. 2009, 20(11):2371-2379.
4. Asai O., Nakatani K., Tanaka T., et al. Decreased renal alpha-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int. 2012, 81(6):539-547.
5. Bellut D., Hlavica M., Schmid C., et al. Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly. Neurosurg. Focus 2010, 29(4):E9.
6. Bernabeu I., Alvarez-Escola C., Quinteiro C., et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J. Clin. Endocrinol. Metab. 2010, 95(1):222-229.
7. Bianchi A., Giustina A., Cimino V., et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J. Clin. Endocrinol. Metab. 2009, 94(6):2015-2022.
8. Blum W.F., Machinis K., Shavrikova E.P., et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J. Clin. Endocrinol. Metab. 2006, 91(10):4171-4174.
9. Bougneres P. The exon-3 deletion of the growth hormone receptor (GHR) gene still has a limited impact in clinical endocrinology. J. Clin. Endocrinol. Metab. 2010, 95(1):56-59.
10. Chang Q., Hoefs S., van der Kemp A.W., et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005, 310(5747):490-493.
11. Dos Santos C., Essioux L., Teinturier C., et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 2004, 36(7):720-724.
12. Eppler E., Shved N., Moret O., et al. IGF-I is distinctly located in the bony fish pituitary as revealed for Oreochromis niloticus, the Nile tilapia, using real-time RT-PCR, in situ hybridisation and immunohistochemistry. Gen. Comp. Endocrinol. 2007, 150(1):87-95.
13. Filopanti M., Olgiati L., Mantovani G., et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J. Clin. Endocrinol. Metab. 2012, 97(2):E165-E172.
14. Freda P.U. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?. Clin. Endocrinol. (Oxf) 2009, 71(2):166-170.
15. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 2010, 95(7):3141-3148.
16. Guler H.P., Schmid C., Zapf J., et al. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc. Natl. Acad. Sci. U.S.A. 1989, 86(8):2868-2872.
17. Hu M.C., Shi M., Zhang J., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2011, 22(1):124-136.
18. Hu M.C., Shiizaki K., Kuro-o M., et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 2013, 75:503-533.
19. Huang P., Stern M.J. FGF signaling in flies and worms: more and more relevant to vertebrate biology. Cytokine Growth Factor Rev. 2005, 16(2):151-158.
20. Imura A., Iwano A., Tohyama O., et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004, 565(1-3):143-147.
21. Ito N., Fukumoto S., Taguchi M., et al. Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr. J. 2007, 54(3):481-484.
22. Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 2011, 149(2):121-130.
23. Jevdjovic T., Bernays R.L., Eppler E. Insulin-like growth factor-I mRNA and peptide in the human anterior pituitary. J. Neuroendocrinol. 2007, 19(5):335-341.
24. Kamenicky P., Dos Santos C., Espinosa C., et al. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur. J. Endocrinol. 2009, 161(2):231-235.
25. Koh N., Fujimori T., Nishiguchi S., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 2001, 280(4):1015-1020.
26. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390(6655):45-51.
27. Kurosu H., Yamamoto M., Clark J.D., et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309(5742):1829-1833.
28. Kurosu H., Ogawa Y., Miyoshi M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281(10):6120-6123.
29. Li S.A., Watanabe M., Yamada H., et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 2004, 29(4):91-99.
30. Matsumura Y., Aizawa H., Shiraki-Iida T., et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 1998, 242(3):626-630.
31. Mercado M., Gonzalez B., Sandoval C., et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J. Clin. Endocrinol. Metab. 2008, 93(9):3411-3415.
32. Neggers S.J., Biermasz N.R., van der Lely A.J. What is active acromegaly and which parameters do we have?. Clin. Endocrinol. (Oxf) 2012, 76(5):609-614.
33. Neidert M.C., Sze L., Zwimpfer C., et al. Soluble alpha-Klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur. J. Endocrinol. 2013, 168(4):575-583.
34. Pantel J., Machinis K., Sobrier M.L., et al. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J. Biol. Chem. 2000, 275(25):18664-18669.
35. Polanska U.M., Edwards E., Fernig D.G., et al. The cooperation of FGF receptor and Klotho is involved in excretory canal development and regulation of metabolic homeostasis in Caenorhabditis elegans. J. Biol. Chem. 2011, 286(7):5657-5666.
36. Ronchi C.L., Arosio M., Rizzo E., et al. Adequacy of current postglucose GH nadir limit (<1microg/l) to define long-lasting remission of acromegalic disease. Clin. Endocrinol. (Oxf) 2007, 66(4):538-542.
37. Schmid C., Krayenbuehl P.A., Bernays R.L., et al. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin. Chem. 2007, 53(8):1484-1488.
38. Semba R.D., Cappola A.R., Sun K., et al. Plasma klotho and mortality risk in older community-dwelling adults. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66(7):794-800.
39. Sze L., Bernays R.L., Zwimpfer C., et al. Excessively high soluble Klotho in patients with acromegaly. J. Intern. Med. 2012, 272(1):93-97.
40. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444(7120):770-774.
41. Wan J., Atzmon G., Hwang D., et al. Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA). J. Clin. Endocrinol. Metab. 2013, 98(1):E77-E81.
42. Wassenaar M.J., Biermasz N.R., Pereira A.M., et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J. Clin. Endocrinol. Metab. 2009, 94(12):4671-4678.
43. Wiesli P., Zwimpfer C., Zapf J., et al. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet. Gynecol. Scand. 2006, 85(8):900-905.
44. Yamazaki Y., Imura A., Urakawa I., et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem. Biophys. Res. Commun. 2010, 398(3):513-518.
45. Zirkzee E.J., Corssmit E.P., Biermasz N.R., et al. Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 2004, 89(9):4320-4324.